Kymera Therapeutics (KYMR) Earnings Analysis
Kymera Therapeutics (KYMR) next reports earnings on 2026-08-10, consensus EPS -0.71706 USD. Last quarter (2026-04-30) it beat with EPS -0.71 USD vs -0.89 USD est (+20.2%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -30.82.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does KYMR next report earnings?
| Next earnings date | 2026-08-10 |
|---|---|
| Consensus EPS estimate | -0.71706 USD |
| Revenue estimate | 0.03B |
KYMR earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-04-30 | -0.71 USD | -0.89 USD | +20.2% | Beat |
| 2026-02-26 | -0.97 USD | -0.78366 USD | -23.8% | Miss |
| 2025-08-11 | -0.95 USD | -0.83 USD | -14.5% | Miss |
| 2025-05-09 | -0.82 USD | -0.92 USD | +10.9% | Beat |
| 2025-02-27 | -0.88 USD | -0.76 USD | -15.8% | Miss |
| 2024-10-31 | -0.82 USD | -0.83 USD | +1.2% | Beat |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
KYMR valuation and analyst view
| Trailing P/E | -30.82 |
|---|---|
| Trailing EPS | -3.23018 USD |
| Price / book | 6.99 |
| Dividend yield | 0.00% |
| Market cap | 9.10B |
| Analyst consensus | Buy (23 buy / 4 hold / 0 sell) |
| Avg price target | 124.63 USD |
Related research pages
Frequently asked questions
When is Kymera Therapeutics (KYMR)'s next earnings date?
Kymera Therapeutics is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.71706 USD and revenue estimate of 0.03B.
Did KYMR beat earnings last quarter?
In its 2026-04-30 report, KYMR posted EPS of -0.71 USD versus a -0.89 USD estimate — a beat of 20.2%.
What is KYMR's earnings track record?
Over the last 6 reported quarters with consensus data, KYMR beat estimates 3 times (50%).
What is KYMR's current P/E ratio and EPS?
KYMR trades at a trailing P/E of -30.82 on trailing EPS of -3.2301774876684624 USD.
What do analysts rate KYMR?
Analyst consensus is "Buy" across 27 ratings (0 strong buy, 23 buy, 4 hold, 0 sell, 0 strong sell). Average 12-month price target: 124.63 USD.